Ensysce Biosciences (ENSC) FCF Margin (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly FCF Margin of 378.46% for Q3 2025, down 34861.0% year-over-year from N/an in Q3 2024, and down 91.74% quarter-over-quarter from 197.37% in Q2 2025.
Ensysce Biosciences (ENSC) FCF Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported FCF Margin for 6 consecutive years, with 378.46% the latest figure, recorded in Q3 2025.
- In Q3 2025, FCF Margin fell 34861.0% year-over-year to 378.46%; the TTM figure through Sep 2025 stood at 156.97% (up 3620.0% YoY), while the FY2024 annual figure was 144.0%, up 33929.0% from the prior year.
- FCF Margin eased to 378.46% in Q3 2025 per ENSC's latest filing, from 197.37% in the prior quarter.
- Across five years, FCF Margin topped out at 29.77% in Q2 2021 and bottomed at 2403.54% in Q3 2022.
- Historically, FCF Margin has averaged 593.05% across 5 years, with a median of 349.86% in 2023.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 211053 bps — and 2023, when it soared 188384 bps.
- Ensysce Biosciences' FCF Margin stood at 230.41% in 2021, then grew by 0 bps to 229.91% in 2022, then tumbled by 52 bps to 349.86% in 2023, then surged by 83 bps to 58.61% in 2024, then plunged by 546 bps to 378.46% in 2025.
- Business Quant data shows ENSC's FCF Margin at 378.46% in Q3 2025, 197.37% in Q2 2025, and 129.37% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -378.46% |
| Jun 30, 2025 | -197.37% |
| Mar 31, 2025 | -129.37% |
| Dec 31, 2024 | -58.61% |
| Sep 30, 2024 | -29.84% |
| Jun 30, 2024 | -1,270.59% |
| Mar 31, 2024 | -1,114.87% |
| Dec 31, 2023 | -349.86% |
| Sep 30, 2023 | -519.69% |
| Jun 30, 2023 | -633.79% |
| Mar 31, 2023 | -456.78% |
| Dec 31, 2022 | -229.91% |
| Sep 30, 2022 | -2,403.54% |
| Jun 30, 2022 | -2,140.30% |
| Mar 31, 2022 | -569.89% |
| Dec 31, 2021 | -230.41% |
| Sep 30, 2021 | -318.53% |
| Jun 30, 2021 | -29.77% |
| Mar 31, 2021 | -206.38% |
| Dec 31, 2020 | -128.18% |